NCT06242834 : Clinical Trial Detail - Cancer Knowledgebase (CKB)

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

NCT ID	NCT06242834
Title	Pembrolizumab and Tazemetostat to Overcome Immune Tolerance Following ASCT or CAR T-cell Therapy in Patients With Aggressive B-Cell Non-Hodgkin's Lymphoma
Recruitment	Recruiting
Gender	both
Phase	Phase II
Variant Requirements	No
Sponsors	Northwestern University
Indications	non-Hodgkin lymphoma diffuse large B-cell lymphoma B-cell lymphoma primary mediastinal B-cell lymphoma diffuse large B-cell lymphoma germinal center B-cell type
Therapies	Pembrolizumab + Tazemetostat
Age Groups:	adult \| senior
Covered Countries	USA

Facility	Status	City	State	Zip	Country	Details
Northwestern University	RECRUITING	Chicago	Illinois	60611	United States	Details
University of Iowa	RECRUITING	Iowa City	Iowa	52242	United States	Details

*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field

NCT06242834Clinical Trial Detail